Company Overview and News

1
Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up

2018-08-07 zacks - 1
Radius Health, Inc. (RDUS - Free Report) reported encouraging results for the second-quarter of 2018, wherein loss was narrower than expected and sales beat estimates.
LLY AMGN GILD LLY RDUS

2
ARMO Biosciences Inc Shares Skyrocket on $1.6 B Eli Lilly Deal

2018-05-11 investorplace
ARMO Biosciences Inc (NASDAQ:ARMO) stock is skyrocketing today on news of a massive deal with Eli Lilly And Co (NYSE:LLY).
ARMO LLY LLY

22
Stagnant Revenues Continue to Hamper the Growth of Pfizer Inc.

2018-05-02 investorplace
Pfizer Inc. (NYSE:PFE) stock tumbled after the New York-based pharma giant released earnings. Although the company beat earnings expectations, PFE revenue growth remained stagnant. This caused the stock to fall almost 5% as the stock price remained range bound.
LLY PFZ MRK LLY 500680 PFE GSK PFIZER

22
Amid Mixed News on Earnings, Merck & Co., Inc. (MRK) Stock Remains Steady

2018-05-01 investorplace
Merck & Co., Inc. (NYSE:MRK) stock saw a tepid reaction as the company released earnings earlier in the morning. Wall Street expressed mixed reviews as the company beat estimates on earnings but disappointed on revenue growth.
LLY PFZ MRK LLY 500680 PFE GSK PFIZER

119
Eli Lilly And Co Produced a Monstrous Q1 Beat, But Is It Enough?

2018-04-24 investorplace
It’s a busy week for pharmaceutical companies, with Eli Lilly And Co (NYSE:LLY), Biogen Inc (NASDAQ:BIIB), and Amgen, Inc. (NASDAQ:AMGN) having released their earnings report today. For Eli Lilly stock, investors sought a definitive sign where the renowned firm was headed. Following a steep drop at the end of January, LLY has trended inside a frustrating consolidation pattern.
LLY AMGN BIIB LLY

128
Is SPDR S&P Pharmaceuticals ETF (XPH) a Hot ETF Right Now?

2018-04-24 zacks
A smart beta exchange traded fund, the SPDR S&P Pharmaceuticals ETF (XPH - Free Report) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the U.S. equity market.
CHTR LLY JAZZ AGN PJP IHE LLY ISRG XPH ACT

2
BRIEF-Lilly Says Galcanezumab Reduced Monthly Migraine Headache Days In Patients With Migraine

2018-04-24 reuters
* AAN 2018: LILLY‘S GALCANEZUMAB SIGNIFICANTLY REDUCED MONTHLY MIGRAINE HEADACHE DAYS IN PATIENTS WITH MIGRAINE WHO PREVIOUSLY FAILED TO RESPOND TO MULTIPLE PREVENTIVE THERAPIES
LLY LLY

104
5 Drug Stocks Poised to Surpass on Earnings This Quarter

2018-04-17 investorplace - 3
The first-quarter earnings season has just kicked off. Per the latest Earnings Preview, the bottom line of S&P 500 companies is expected to increase at a highly impressive rate of 16.6% on a year-over-year basis. This prospective upside marks the maximum quarterly earnings growth pace in seven years.
LLY PFZ PETX CTLT ABBV LLY 500680 PFE PFIZER ABBV

109
Radius Health Down on Negative CHMP Opinion for Lead Drug

2018-03-23 zacks
Shares of Radius Health (RDUS - Free Report) fell 4% after the company suffered a setback once again in Europe.
LLY REGN AMGN LLY RDUS

111
Radius Health Announces Positive Data on Lead Drug Tymlos

2018-03-19 zacks
Radius Health, Inc. (RDUS - Free Report) announced positive results from the phase III study, ACTIVExtend, at ENDO 2018, the Endocrine Society's 100th Annual Meeting and Expo in Chicago.
LLY REGN AMGN LLY GM RDUS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to EPA:LLY / Eli Lilly & Co. on message board site Silicon Investor.

Gardening and Especially Tomato Growing Gardening and Especially Tomato Growing Gardening and Especially Tomato Growing Specially made small condoms for Soy Boy Libtards Specially made small condoms for Soy Boy Libtards Specially made small condoms for Soy Boy Libtards
Anything graphite based, CCB, Zen and hopefully much more. Anything graphite based, CCB, Zen and hopefully much more. Anything graphite based, CCB, Zen and hopefully much more. Silicon Investor - User Site Discussion - Generally Unmodera Silicon Investor - User Site Discussion - Generally Unmodera Silicon Investor - User Site Discussion - Generally Unmodera
For the Psychologically Oriented For the Psychologically Oriented For the Psychologically Oriented Porkbelly futures u0026 political ramifications of Pork Tarrifs Porkbelly futures u0026 political ramifications of Pork Tarrifs Porkbelly futures u0026 political ramifications of Pork Tarrifs
Hemp based foods from Naturally Splendid Enterprises Ltd. Hemp based foods from Naturally Splendid Enterprises Ltd. Hemp based foods from Naturally Splendid Enterprises Ltd. Nancy Pelosi Is Mentally ILL! Nancy Pelosi Is Mentally ILL! Nancy Pelosi Is Mentally ILL!
How Quickly Can Obama Totally Destroy the US? How Quickly Can Obama Totally Destroy the US? How Quickly Can Obama Totally Destroy the US? Digital Ally Inc. - DGLY Digital Ally Inc. - DGLY Digital Ally Inc. - DGLY